Floatz logo

Capecitabine

Carcinosarcoma, Ovarian

ARCAGY/ GINECO GROUPSmall moleculePhase 2/3Active
BB
64/ 100
Provisional rating · Methodology v0.2

Rating breakdown

Clinical Evidence
49/ 100
Competitive Position
95/ 100

Competitive context

0 Active assets in the Carcinosarcoma, Ovarian cohort.

Asset / SponsorPhaseRating
Trabectedin
Fondazione Policlinico Universitario Agostino Gemelli IRCCS
Phase 2B
Galunisertib
University of Oklahoma
Phase 1CC

Same molecule, other indications

Capecitabine is also rated in:

Locally Advanced Rectal CancerDormant
BBB
Indicative ·
75 / 100
View asset →
colorectal neoplasmDormant
BBB
Indicative ·
74 / 100
View asset →
rectal carcinomaDormant
BBB
Indicative ·
73 / 100
View asset →

Need depth?

Order a full diligence report on this asset.

Order report →

Are you the sponsor?

Submit your data room for a Verified Rating. The public-data rating remains visible alongside.

Contact →